Neogene Therapeutics IPO

Neogene Therapeutics develops personalized engineered T cell therapies for a broad spectrum of cancers.

Neogene Therapeutics Funding Rounds and IPO Valuation

Date	Funding Round	Funding Raised	Price per Share	IPO Valuation
9/14/2020	Series A	$110MM raised	$XXX.XX	$XXX.XX
5/23/2019	Series Seed	$15MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Neogene Therapeutics has raised $125MM with the following series:
$15MM raised for Series Seed,$110MM raised for Series A.

Neogene Therapeutics was founded in 2018.

Updated on: Jun 12, 2022